CStone Pharma of Suzhou has dosed the first patient in an Australian Phase I clinical trial of CS3006, a selective small molecule inhibitor of mitogen-activated protein kinase (MEK). CS3006 is CStone’s third candidate to start human testing (all of them in Australia). The others are: CS1003, a programmed death-1 (PD-1) inhibitor and CS1002, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) inhibitor. CStone plans to tests its candidates as monotherapies and combination therapies, both in China and globally.
Source: China Biotoday
